Papers by Enas A Abdul-Baki
Molecular Biology Reports, 2020
MicroRNAs (miRNAs) play important roles in liver pathologies and they are potential biomarkers fo... more MicroRNAs (miRNAs) play important roles in liver pathologies and they are potential biomarkers for diagnosis of liver diseases progression. Changes in miRNA sera expression can be used as non-invasive biomarkers for hepatocellular carcinoma (HCC). The aim of the study was to identify the miRNome profiling of HCC and its diagnostic value in distinguishing HCC from healthy individuals. Expression profiles of miRNAs in serum samples of 20 HCC patients and 10 healthy controls were detected. Whole miRNome profiling was done using next generation sequencing. Receiver operating characteristic (ROC) analysis was performed to assess the diagnostic performance of the deregulated miRNAs for discriminating HCC cases from healthy controls. MiRNA 142 was highly expressed in HCC (P value = 0.023) while miRNAs 191, 22, and 126 were higher in the controls (P value = 0.005, 0.034, 0.010 respectively). We have identified 5 novel miRNAs and they were highly expressed in HCC than controls. Analysis of ROC curve demonstratedthat these deregulated miRNAs can be used as a reliable biomarker for detection of HCC with high diagnostic accuracy (AUC = 0.93). We have detected a panel of serum miRNAs that can be used as a reliable noninvasive screening biomarker of HCC. The study recommends further research to shed light on a possible role of the newly discovered novel miRNAs in HCC pathogenesis.
Journal of Cancer Science & Therapy, 2017
Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like Egypt sin... more Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like Egypt since patients are usually admitted in late stage with bad prognosis and short overall survival. Because of genetic predisposition of CRC and introduction of advanced molecular techniques, efforts are directed to screen for potential pathogenic or disease-causing variants in CRC patients Methods: DNA was isolated from formalin fixed paraffin embedded tissue sections collected from 24 CRC confirmed diagnosed patients. TruSight CRC panel (Illumina) was used for detection of different variants in 15 genes. The generated reads were obtained from Illumina Miseq were clustered into single nucleotide polymorphism (SNPs) and small insertions/deletions (Indels). Further pathogenic variants with somatic and germline mutations were identified according to the recommended criteria. Some CRC patients were subjected to anti-EGFR target therapy. Results: Most of the variants were detected in TP53 gene 140 variants (65%); 105 short deletions none of them was pathogenic, 29 missense mutations and 6 SNPs at splicing sites. Next, ERBB2 has got 17 variants (8.8%) (missense and splicing), 8 of them were damaging disease causing variants. Besides, 16 pathogenic variants were identified in 12 patients (6 in TP53 and 7 in KRAS). Some pathogenic variants were not reported before in CRC e.g. TP53 C>A, rs121912654, Val157Phe. Additionally, patients carried different KRAS wild mutations showed variable response to anti-EGFR target therapy. Conclusion: The most affected pathway in CRC was TP53 pathway followed by ERBB2, NRAS, KRAS and PIK3CA genes. Variable response to target therapy suggested dependence on the type of pathogenic variant identified, also a possible role of ERBB2 which had a significant variant frequency. NRAS. The prevalence rate of TP53 mutation in Arab population is 52.5% compared to 47.5% in matched Western population [7]. TP53 mutations have roles in determining progression, invasiveness and also metastasis of CRC. So, CRC patients with mutant TP53 have more progressive phenotype and poorer survival than those with TP53 wild type [8]. The phosphatidylinositol 3-kinase/Akt/mammalian target of
Biopolymers and Cell, 1998
Molecular Biology Reports, 2020
The correct spelling of the 7th authors' name is Mona Watany.
Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry, 2018
Background: MicroRNAs (miRNAs) are endogenous noncoding RNAs, which play an essential role in the... more Background: MicroRNAs (miRNAs) are endogenous noncoding RNAs, which play an essential role in the regulation of gene expression. Aim of the work: To analyze miRNA expression profile in the childhood B acute lymphoblastic leukemia (B-ALL). To understand the functional regulatory effects of differential miRNAs on their targets and its clinical significance and novel analytical method to combine their expression profiles. Patients and Methods: In this study, we determined the relative expression analysis of miRNA and mRNA profiles in 20 childrenB-ALL patients. Through the use of miRNA microarray technology and according to their miRNA profile.The best characterized non-coding RNA family consists in humans of about 1400 microRNAs for which abundant evidence have demonstrated fundamental importance in normal development, differentiation, growth control and inhuman diseases such as cancer. Results: miR-100, miR-146a, miR-128a, miR-128b, miR181a, miR-34, miR-193a, miR-193b, miR-151, miR-13...
The American Journal of Tropical Medicine and Hygiene
To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with C... more To date, no antiviral therapy has shown proven clinical effectiveness in treating patients with COVID-19. We assessed the efficacy of remdesivir in hospitalized Egyptian patients with COVID-19. Patients were randomly assigned at a 1:1 ratio to receive either remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30–60 minutes) in addition to standard care or standard care alone. The primary outcomes were the length of hospital stay and mortality rate. The need for mechanical ventilation was assessed as a secondary outcome. Two hundred patients (100 in each group) completed the study and were included in the final analysis. The remdesivir group showed a significantly lower median duration of hospital stay (10 days) than the control group (16 days; P < 0.001). Eleven of the patients in the remdesivir group needed mechanical ventilation compared with eight patients in the control group (P = 0.469). The mortality rate was comparabl...
Background and Aims: To our knowledge, no study has investigated neither how Moringaleaf extract ... more Background and Aims: To our knowledge, no study has investigated neither how Moringaleaf extract modulates the immune system in normal nor diabetic subjects. Materials and Methods: Diabetes was induced by a single intraperitoneal dose of alloxan (150 mg/kg). Adose of 100 mg/kg of MO extract was orally administered for diabetic treated mice. Theprofile of glucose and insulin was evaluated. The activity of superoxide dismutase, catalase,glutathione peroxidase, and glutathione enzymes was determined. Liver function wasmonitored by measuring levels of alkaline phosphatase, glutamine pyruvate transaminase,and glutamic oxaloacetic transaminase. The percentage of single-or double-positive cells ofeach of CD8+/CD4+, CD117+/Sca-1+, Sca-1+/CD34+, CD11b+/Ly6-G+, CD11c+/CD11b+, andCD34+/CD117+ was investigated by flow cytometry in the peripheral blood. Results: MOpromotes the activity of both CD4+ and CD8+ T cells in diabetic treated mice that may occurthrough the Sca-1+CD117+ stem cell factors. Administration of MO leaf extract enhanced thepercentage of the endothelial progenitors (CD34+CD117+) and mature endothelial cells(CD34+CD117-). Moringa also increased the percentage of blood-derived circulating
angiogenic cells (Sca-1+/CD34+). Discussion and Conclusions: This study shed light for thefirst time on how MO affects different immune cells; the knowledge gained may help toovercome diabetes and its complications.Keywords: CD8+CD4+ T cells; lipid peroxidation, circulating angiogenic cells; immunemodulation
Abstract
Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like ... more Abstract
Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like Egypt since patients
are usually admitted in late stage with bad prognosis and short overall survival. Because of genetic predisposition
of CRC and introduction of advanced molecular techniques, efforts are directed to screen for potential pathogenic
or disease-causing variants in CRC patients
Methods: DNA was isolated from formalin fixed paraffin embedded tissue sections collected from 24 CRC
confirmed diagnosed patients. TruSight CRC panel (Illumina) was used for detection of different variants in 15
genes. The generated reads were obtained from Illumina Miseq were clustered into single nucleotide polymorphism
(SNPs) and small insertions/deletions (Indels). Further pathogenic variants with somatic and germline mutations
were identified according to the recommended criteria. Some CRC patients were subjected to anti-EGFR target
therapy.
Results: Most of the variants were detected in TP53 gene 140 variants (65%); 105 short deletions none of them
was pathogenic, 29 missense mutations and 6 SNPs at splicing sites. Next, ERBB2 has got 17 variants (8.8%)
(missense and splicing), 8 of them were damaging disease causing variants. Besides, 16 pathogenic variants were
identified in 12 patients (6 in TP53 and 7 in KRAS). Some pathogenic variants were not reported before in CRC e.g.
TP53 C>A, rs121912654, Val157Phe. Additionally, patients carried different KRAS wild mutations showed variable
response to anti-EGFR target therapy.
Conclusion: The most affected pathway in CRC was TP53 pathway followed by ERBB2, NRAS, KRAS and
PIK3CA genes. Variable response to target therapy suggested dependence on the type of pathogenic variant
identified, also a possible role of ERBB2 which had a significant variant frequency.
Background: Granulocyte colony stimulating factor (G-CSF) is used in clinical practice to mobiliz... more Background: Granulocyte colony stimulating factor (G-CSF) is used in clinical practice to mobilize neutrophils alone or in combination with chemotherapy. However, its influence in physiological indices has not been addressed well in certain animal models such as Wistar rats. Aims: To evaluate the single and combinatorial effects of G-CSF and cyclophosphamide (CTX) on physiological indices in Wistar rat. Materials and Methods: Naïve female Wistar rats were treated with subcutaneous injection of pharmaceutical benefits scheme, (5 μL/day/rat) G-CSF for 5 consecutive days and single intraperitoneal injection of CTX (4 mg/rat). Body weights were obtained daily. Rats were sacrificed 1-day after the last injection to obtain different organ weight and to analyze the physiological indices in plasma and the liver. Results: G-CSF alone induced increases in body weight, splenomegaly, white blood cells, platelets, and alanine aminotransferase (ALT) activity. It, however, decreased neutrophils and monocytes, aspartate aminotransferase (AST) activity, red blood cells and hemoglobin level. CTX alone induced decreases in body weight, white blood cells, neutrophils, red blood cells and hemoglobin level. It, however, increased spleen weight, lymphocytes, monocytes, ALT activity and AST. G-CSF + CTX induced increases in body weight, splenomegaly, lymphocytes and ALT. It, however, decreased white blood cells, platelets number, neutrophils, monocytes, red blood cells and hemoglobin level. Conclusion: Among different physiological indices, treatment with single or combinatorial G-CSF increases the total number of white blood cells in Wistar rats which need to be considered while using this model animal disease.
Background: Granulocyte colony stimulating factor (G-CSF) is used in clinical practice to mobiliz... more Background: Granulocyte colony stimulating factor (G-CSF) is used in clinical practice to mobilize neutrophils alone or in combination with chemotherapy. However, its influence in physiological indices has not been addressed well in certain animal models such as Wistar rats. Aims: To evaluate the single and combinatorial effects of G-CSF and cyclophosphamide (CTX) on physiological indices in Wistar rat. Materials and Methods: Naïve female Wistar rats were treated with subcutaneous injection of pharmaceutical benefits scheme, (5 μL/day/rat) G-CSF for 5 consecutive days and single intraperitoneal injection of CTX (4 mg/rat). Body weights were obtained daily. Rats were sacrificed 1-day after the last injection to obtain different organ weight and to analyze the physiological indices in plasma and the liver. Results: G-CSF alone induced increases in body weight, splenomegaly, white blood cells, platelets, and alanine aminotransferase (ALT) activity. It, however, decreased neutrophils and monocytes, aspartate aminotransferase (AST) activity, red blood cells and hemoglobin level. CTX alone induced decreases in body weight, white blood cells, neutrophils, red blood cells and hemoglobin level. It, however, increased spleen weight, lymphocytes, monocytes, ALT activity and AST. G-CSF + CTX induced increases in body weight, splenomegaly, lymphocytes and ALT. It, however, decreased white blood cells, platelets number, neutrophils, monocytes, red blood cells and hemoglobin level. Conclusion: Among different physiological indices, treatment with single or combinatorial G-CSF increases the total number of white blood cells in Wistar rats which need to be considered while using this model animal disease.
Uploads
Papers by Enas A Abdul-Baki
angiogenic cells (Sca-1+/CD34+). Discussion and Conclusions: This study shed light for thefirst time on how MO affects different immune cells; the knowledge gained may help toovercome diabetes and its complications.Keywords: CD8+CD4+ T cells; lipid peroxidation, circulating angiogenic cells; immunemodulation
Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like Egypt since patients
are usually admitted in late stage with bad prognosis and short overall survival. Because of genetic predisposition
of CRC and introduction of advanced molecular techniques, efforts are directed to screen for potential pathogenic
or disease-causing variants in CRC patients
Methods: DNA was isolated from formalin fixed paraffin embedded tissue sections collected from 24 CRC
confirmed diagnosed patients. TruSight CRC panel (Illumina) was used for detection of different variants in 15
genes. The generated reads were obtained from Illumina Miseq were clustered into single nucleotide polymorphism
(SNPs) and small insertions/deletions (Indels). Further pathogenic variants with somatic and germline mutations
were identified according to the recommended criteria. Some CRC patients were subjected to anti-EGFR target
therapy.
Results: Most of the variants were detected in TP53 gene 140 variants (65%); 105 short deletions none of them
was pathogenic, 29 missense mutations and 6 SNPs at splicing sites. Next, ERBB2 has got 17 variants (8.8%)
(missense and splicing), 8 of them were damaging disease causing variants. Besides, 16 pathogenic variants were
identified in 12 patients (6 in TP53 and 7 in KRAS). Some pathogenic variants were not reported before in CRC e.g.
TP53 C>A, rs121912654, Val157Phe. Additionally, patients carried different KRAS wild mutations showed variable
response to anti-EGFR target therapy.
Conclusion: The most affected pathway in CRC was TP53 pathway followed by ERBB2, NRAS, KRAS and
PIK3CA genes. Variable response to target therapy suggested dependence on the type of pathogenic variant
identified, also a possible role of ERBB2 which had a significant variant frequency.
angiogenic cells (Sca-1+/CD34+). Discussion and Conclusions: This study shed light for thefirst time on how MO affects different immune cells; the knowledge gained may help toovercome diabetes and its complications.Keywords: CD8+CD4+ T cells; lipid peroxidation, circulating angiogenic cells; immunemodulation
Background: Colorectal carcinoma (CRC) is a burden problem in a developing country like Egypt since patients
are usually admitted in late stage with bad prognosis and short overall survival. Because of genetic predisposition
of CRC and introduction of advanced molecular techniques, efforts are directed to screen for potential pathogenic
or disease-causing variants in CRC patients
Methods: DNA was isolated from formalin fixed paraffin embedded tissue sections collected from 24 CRC
confirmed diagnosed patients. TruSight CRC panel (Illumina) was used for detection of different variants in 15
genes. The generated reads were obtained from Illumina Miseq were clustered into single nucleotide polymorphism
(SNPs) and small insertions/deletions (Indels). Further pathogenic variants with somatic and germline mutations
were identified according to the recommended criteria. Some CRC patients were subjected to anti-EGFR target
therapy.
Results: Most of the variants were detected in TP53 gene 140 variants (65%); 105 short deletions none of them
was pathogenic, 29 missense mutations and 6 SNPs at splicing sites. Next, ERBB2 has got 17 variants (8.8%)
(missense and splicing), 8 of them were damaging disease causing variants. Besides, 16 pathogenic variants were
identified in 12 patients (6 in TP53 and 7 in KRAS). Some pathogenic variants were not reported before in CRC e.g.
TP53 C>A, rs121912654, Val157Phe. Additionally, patients carried different KRAS wild mutations showed variable
response to anti-EGFR target therapy.
Conclusion: The most affected pathway in CRC was TP53 pathway followed by ERBB2, NRAS, KRAS and
PIK3CA genes. Variable response to target therapy suggested dependence on the type of pathogenic variant
identified, also a possible role of ERBB2 which had a significant variant frequency.